Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Management of myelofibrosis after ruxolitinib failure.

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.

Carotenoid Intake and Circulating Carotenoids Are Inversely Associated with the Risk of Bladder Cancer: A Dose-Response Meta-analysis.

Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported.

Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.

Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.

Overcoming Barriers for Latinos on Cancer Clinical Trials.

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.

Proactive steps to optimize the management of polycythemia vera and myelofibrosis.